This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
by Zacks Equity Research
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
AZNNegative Net Change LLYPositive Net Change HRTXNegative Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals
Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M
by Zacks Equity Research
Simulation Plus (SLP) acquires Pro-ficiency from QHP Capital for $100 million in an all-cash transaction.
NVDAPositive Net Change SLPNegative Net Change MSINegative Net Change ANETPositive Net Change
biotechnology biotechs computers pharmaceuticals tech-stocks
Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANI Pharmaceuticals (ANIP) stock based on the movements in the options market lately.
ANIPNegative Net Change
pharmaceuticals
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
by Zacks Equity Research
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
PFENegative Net Change SRPTPositive Net Change PTCTNegative Net Change CAPRPositive Net Change
pharmaceuticals
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
RDNTNegative Net Change USPHNegative Net Change HAEPositive Net Change LNTHNegative Net Change
earnings investing medical medical-devices pharmaceuticals
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
by Kinjel Shah
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
BIIBPositive Net Change LLYPositive Net Change PRTANegative Net Change ACIUPositive Net Change
pharmaceuticals
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
REGNNegative Net Change SNYNegative Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
by Zacks Equity Research
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
CGENPositive Net Change APLSPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug
by Mark Vickery
Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.
BIIBPositive Net Change AAPLPositive Net Change LLYPositive Net Change
artificial-intelligence communications medical pharmaceuticals tech-stocks
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
by Sheraz Mian
Today's Research Daily features an earnings season update and new research reports on Broadcom (AVGO), Johnson & Johnson (JNJ) and Verizon (VZ), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Frequency Electronics, Inc. (FEIM).
NEEPositive Net Change JNJPositive Net Change VZPositive Net Change BDXNegative Net Change ENBNegative Net Change AVGOPositive Net Change FEIMNegative Net Change TAYDNegative Net Change
communications computers industrial-products pharmaceuticals semiconductor
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
by Zacks Equity Research
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
BMYNegative Net Change GERNNegative Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
by Zacks Equity Research
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
RHHBYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
by Zacks Equity Research
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
CGENPositive Net Change CDXCPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
by Zacks Equity Research
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.
AZNNegative Net Change NERVPositive Net Change MRNSNegative Net Change KRYSPositive Net Change
pharmaceuticals
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
by Zacks Equity Research
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
by Zacks Equity Research
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
AZNNegative Net Change GSKNo Net Change PFENegative Net Change MRNANegative Net Change
pharmaceuticals
Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), TotalEnergies SE (TTE) and U.S. Bancorp (USB), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
FNegative Net Change NVONegative Net Change USBNegative Net Change MFCNegative Net Change FANGNegative Net Change BDLNegative Net Change TTENegative Net Change
finance oil-energy pharmaceuticals restaurants retail
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
by Kinjel Shah
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
AZNNegative Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Replimune (REPL) Gains on Positive Data From Melanoma Study
by Zacks Equity Research
Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
BMYNegative Net Change KRYSPositive Net Change REPLPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
by Zacks Equity Research
Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.
JNJPositive Net Change HALONegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
by Zacks Equity Research
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
GSKNo Net Change BIIBPositive Net Change AMGNNegative Net Change VKTXNegative Net Change VIRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
by Zacks Equity Research
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
NERVPositive Net Change KRYSPositive Net Change VIRNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
by Zacks Equity Research
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
AMGNNegative Net Change HRTXNegative Net Change MRNSNegative Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals